XML 148 R33.htm IDEA: XBRL DOCUMENT v3.25.0.1
Stock-Based Compensation (Tables)
9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]    
Schedule of Stock-based Compensation Expense
Stock-based compensation expense was as follows:
 
    
Three Months Ended
September 30,
    
Nine Months Ended
September 30,
 
(in thousands)
  
2024
    
2023
    
2024
    
2023
 
Research and development
   $ 312      $ 3,254      $ 232      $ 10,191  
General and administrative
     4,635        7,214        15,657        20,594  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total stock-based compensation expense
   $ 4,947      $ 10,468      $ 15,889      $ 30,785  
  
 
 
    
 
 
    
 
 
    
 
 
 
Stock-based compensation expense was as follows:
 
    
Years Ended December 31,
 
(in thousands)
  
 2023 
    
 2022 
 
Research and development
   $ 13,167      $ 14,014  
General and administrative
     27,612        27,301  
  
 
 
    
 
 
 
Total stock-based compensation expense
   $ 40,779      $ 41,315  
  
 
 
    
 
 
 
Summary of Restricted Common Stock Activity
The following table summarizes restricted common stock activity for the nine months ended September 30, 2024:
 
 
  
Shares
 
  
Weighted
Average
Grant Date
Fair Value
 
Unvested at January 1, 2024
     141,516     
$
200.79  
Granted
     10,652        17.71  
Forfeited
     (48,999 )      191.82  
Vested
     (54,469 )      198.95  
  
 
 
    
 
 
 
Unvested at September 30, 2024
     48,700     
$

171.35  
  
 
 
    
 
 
 
The following table summarizes restricted common stock activity for the year ended December 31, 2023:
 
 
  
Shares
 
  
Weighted
Average
Grant Date
Fair Value
 
Unvested at January 1, 2023
     97,352      $ 316.25  
Granted
     99,130        138.46  
Forfeited
     (14,901 )      263.58  
Vested
     (40,065 )      304.52  
  
 
 
    
 
 
 
Unvested at December 31, 2023
     141,516      $ 200.79  
  
 
 
    
 
 
 
Summary of Stock Option Activity
The following table summarizes stock option activity (in thousands, except share and per share data):
 
    
Shares
    
Weighted
Average
Exercise
Price
    
Weighted
Average
Contractual
Life (in years)
    
Aggregate
Intrinsic
Value
 
Options outstanding at January 1, 2024
     453,902      $ 317.63        7.95      $ —   
Granted
     —         —         —         —   
Exercised
     —         —         —         —   
Forfeited
     (189,901 )      260.36        —         —   
  
 
 
    
 
 
    
 
 
    
 
 
 
Options outstanding at September 30, 2024
     264,001      $ 358.80        6.88      $ —   
  
 
 
    
 
 
    
 
 
    
 
 
 
Options vested and exercisable at September 30, 2024
     199,117      $ 402.73        6.56      $ —   
The following table summarizes stock option activity (in thousands, except share and per share data):
 
 
  
Shares
 
  
Weighted
Average
Exercise
Price
 
  
Weighted
Average
Contractual
Life
 
  
Aggregate
Intrinsic
Value
 
Options outstanding at January 1, 2023
     344,469      $ 409.63        8.3      $ 786  
Granted
     164,319        143.52        —         57  
Exercised
     —         —         —         —   
Forfeited
     (54,886 )
 
     373.75        —         82  
  
 
 
    
 
 
    
 
 
    
 
 
 
Options outstanding at December 31, 2023
     453,902      $ 317.63       
7.9
     $ —   
  
 
 
    
 
 
    
 
 
    
 
 
 
Options vested and exercisable at December 31, 2023
     197,136      $ 433.78        7.2      $ —   
Schedule of Estimated Fair Value Weighted-Average Assumptions Using Black-Scholes Option-Pricing Model  
The fair value was estimated on the date of grant using the Black-Scholes option-pricing model, with the following weighted-average assumptions:
 
 
  
Years Ended December 31,
 
 
  
 2023 
 
 
 2022 
 
Expected term (in years)
     6.11       6.07  
Expected volatility
     94     90
Risk-free interest rate
     3.52     2.00
Expected dividend yield
     —        —   
Fair value of common stock
   $ 143.52     $ 172.04